The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?
Merck MRK announced that the FDA has accepted its regulatory filing seeking approval for the subcutaneous (under the skin or SC) formulation of the blockbuster drug Keytruda (pembrolizumab). This ...
Hosted on MSN
Alvotech and Dr. Reddy’s partner to co-develop biosimilar candidate for Merck's Keytruda
Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to co-develop and commercialize a biosimilar of Merck's (NYSE:MRK) cancer drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results